Medivation (MDVN) : Net money flow in Medivation (MDVN) was negative ($3.39 million) and the inflow of money on uptick was $6.79 million, whereas, the outflow of money on downticks amounted to $10.19 million on Thursday. The traders used every opportunity of price strength in the stock to sell their positions, hence, the total uptick to downtick ratio was 0.67. The block trades show that the large investors, were aggressive sellers in the stock. On the other hand, the total value of block trades done on downticks was $2.55 million. The money flow in block trades was negative ($2.55). Medivation (MDVN) gained $0.28 cent during the day and reached $61.85, a gain of 0.45% over the previous day.
The stock has recorded a 20-day Moving Average of 2.69% and the 50-Day Moving Average is 2.27%. Shares have rallied 14.71% from its 1 Year high price. On Jul 7, 2016, the shares registered one year high at $62.98 and the one year low was seen on Feb 9, 2016. The 50-Day Moving Average price is $60.20 and the 200 Day Moving Average price is recorded at $47.44.
Medivation (NASDAQ:MDVN): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $61.91 and $61.55 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $62.03. The buying momentum continued till the end and the stock did not give up its gains. It closed at $61.74, notching a gain of 0.28% for the day. The total traded volume was 976,773 . The stock had closed at $61.57 on the previous day.
In an insider trading activity, The officer (SVP, General Counsel & Crp Sec), of Medivation, Inc., Powell Andrew Kenneth William had unloaded 2,578 shares at $60.42 per share in a transaction on June 6, 2016. The total value of transaction was $155,763. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company in collaboration with Astellas Pharma, Inc. has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe, and other countries worldwide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company in collaboration with Astellas is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. The Company has licensed exclusive worldwide rights to pidilizumab, an immune modulatory, anti-Programmed Death-1 (PD-1) monoclonal antibody for all potential indications from CureTech, Ltd.